Overview

* QuidelOrtho ( QDEL ) Q2 revenue of $614 mln beats analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus at $0.12, per LSEG data

Outlook

* QuidelOrtho ( QDEL ) reiterates full-year 2025 revenue guidance of $2.60 - $2.81 bln

* Company expects full-year adjusted EBITDA of $575 - $615 mln

* QuidelOrtho ( QDEL ) anticipates adjusted diluted EPS of $2.07 - $2.57 for 2025

* Company sees full-year adjusted EBITDA margin at 22%

Result Drivers

* COST SAVINGS - Achieved $100 mln annualized cost savings from initiatives announced in 2024, improving adjusted EBITDA margin by 330 basis points

* LABS REVENUE GROWTH - Labs revenue grew 4% as reported and 5% in constant currency, indicating strong performance in this segment

* REVENUE DECLINE - Total revenue decreased due to lower COVID-19 and Donor Screening revenue compared to the prior year period

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $613.90 $611.20

Revenue mln mln (9

Analysts

)

Q2 Beat $0.12 $0.01 (7

Adjusted Analysts

EPS )

Q2 EPS -$3.77

Q2 Net -$255.40

Income mln

Q2 Basic -$3.77

EPS

Q2 -$180.70

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for QuidelOrtho Corp ( QDEL ) is $50.00, about 51.8% above its August 4 closing price of $24.11

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)